Tocilizumab Withdrawal Post Remission in Still's Disease Tocilizumab Withdrawal Post Remission in Still's Disease
Longer tocilizumab administration intervals and lower prednisolone doses seemed pivotal for successful tocilizumab withdrawal while maintaining remission in patients with AOSD.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 11, 2024 Category: Allergy & Immunology Tags: Rheumatology Clinical Summary Source Type: news
COPD exacerbations: BET with prednisolone noninferior to ST COPD exacerbations: BET with prednisolone noninferior to ST
Results of a randomized trial suggest that blood eosinophil-directed prednisolone can be an option to reduce glucocorticoid use in COPD patients.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 19, 2023 Category: Consumer Health News Tags: Pulmonary Medicine Source Type: news
Low-Dose Steroids May Not Increase CV Risk in RA Low-Dose Steroids May Not Increase CV Risk in RA
A daily prednisolone dose of less than 5 mg was not associated with increased cardiovascular risk, whereas a dose of 5 mg or more doubled the risk for major adverse cardiovascular events.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - August 7, 2023 Category: Rheumatology Tags: Rheumatology News Source Type: news
Steroid Tapering Called Safe in Older RA Patients
(MedPage Today) -- Most rheumatoid arthritis (RA) patients 65 and older who had 5 mg/day of prednisolone added to standard care were successfully weaned from the steroid without seeing substantial increases in disease activity, researchers said... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - August 7, 2023 Category: Primary Care Source Type: news
PET confirms efficacy of first-line cardiac sarcoidosis treatment
FDG-PET imaging has shown for the first time that prednisolone is a potent therapeuti...Read more on AuntMinnie.comRelated Reading:
PET reveals thermal burns due to multiple ICD shocks
Does the keto diet cloud brain PET imaging?
Keto diet improves PET/CT of cardiac sarcoidosis
3D T2 maps enhance assessment of myocarditis on MRI
What is PET/MRI's value for cardiac sarcoidosis? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 21, 2023 Category: Radiology Source Type: news
FDA Approves Lynparza for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
TUESDAY, June 6, 2023 -- The U.S. Food and Drug Administration approved Lynparza (olaparib) with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated, metastatic, castration-resistant... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 6, 2023 Category: General Medicine Source Type: news
FDA Approves Lynparza (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lynparza combination showed a clinically meaningful reduction in risk of disease progression or death in these patients in the Phase 3 PROpel trial
First approval of a PARP inhibitor in combination with a new hormonal agent in mCRPC
RAHWAY,... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 1, 2023 Category: Drugs & Pharmacology Source Type: news
Janssen Marks First Approval Worldwide for AKEEGA ® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorization for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations
BEERSE, Belgium, 21 April 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has granted marketing authorisation for AKEEGA® (niraparib and abiraterone acetate [AA]), in the form of a dual action tablet (DAT), given with prednisone or prednisolone, for the treatment of adults with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.2Prostate cancer is the most common cancer in men in Europe, and the sixth-highest cause of cancer-related death worldwide.1...
Source: Johnson and Johnson - April 21, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news
Johnson & Johnson Reports Q1 2023 Results
New Brunswick, N.J. (April 18, 2023) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2023. “Our first quarter results demonstrate strong performance across all three segments of our business and reflect the dedication of Johnson & Johnson colleagues around the world,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “With this momentum, I look forward to the remainder of the year, one filled with exciting catalysts that will create both near- and long-term value for patients and all of our stakeholders.”OVERALL FINANCIAL RESULTSQ1($ in Millions, except EPS)2...
Source: Johnson and Johnson - April 18, 2023 Category: Pharmaceuticals Tags: Financial Source Type: news
Janssen Submits New Drug Application to the U.S. Food and Drug Administration Seeking Approval of Niraparib and Abiraterone Acetate Dual-Action Tablet, Plus Prednisone, as a First-Line Targeted Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with BRCA Gene Mutations
RARITAN, N.J., February 28, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of niraparib in combination with abiraterone acetate, in the form of a dual-action tablet (DAT), plus prednisone, for the treatment of patients with BRCA-positive metastatic castration-resistant prostate cancer (mCRPC). If approved, this will be the first DAT formulation available in the U.S. to patients with mCRPC with BRCA mutations, which are a type of homologous recombination repair (HRR) gene alt...
Source: Johnson and Johnson - March 1, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Receives Positive CHMP Opinion for AKEEGA ® (Niraparib and Abiraterone Acetate Dual Action Tablet) Plus Prednisone or Prednisolone for the Treatment of Adult Patients with BRCA1/2 Gene-Mutated Metastatic Castration Resistant Prostate Cancer
BEERSE, Belgium, 24 February 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorisation for AKEEGA® (niraparib and AA), in the form of a DAT, given with P or prednisolone, for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.[1]Niraparib is a highly selective poly adenosine diphosphate-ribose polymerase (PARP) inhibi...
Source: Johnson and Johnson - February 27, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
SAN FRANCISCO, February 16, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 MAGNITUDE study evaluating the investigational use of niraparib, a highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) with or without specific homologous recombination repair (HRR) gene alterations, including BRCA mutations. Results will be featured today in a Rapid Abstract Session (Abstract #170) at the American Society of Clinica...
Source: Johnson and Johnson - February 16, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Benefits and Risks of Low-Dose, Add-On Prednisolone in Older Patients With Rheumatoid Arthritis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - November 24, 2022 Category: Orthopaedics Tags: CME Article Source Type: news
Potential relationship between the dosage of prednisolone and delayed healing at tooth extraction: A retrospective study
Conclusion The results of this study suggested that delayed healing following tooth extractions in patients taki ng prednisolone was related to a dosage of 8.0 mg/day or higher and osteosclerotic changes (Source: Dental Technology Blog)
Source: Dental Technology Blog - September 26, 2022 Category: Dentistry Source Type: news
Low-Dose Prednisolone Shows Subacute Thyroiditis Noninferiority Low-Dose Prednisolone Shows Subacute Thyroiditis Noninferiority
Results from a randomized study of 36 adults with subacute thyroiditis showed that starting patients on a daily prednisolone dose of 15 mg/day was noninferior to starting them on a daily 30-mg dose.First Look (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - July 20, 2022 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
